Increasing evidence suggests that newer classes of antiglycemic agents, such as peroxisome proliferator-activated receptor agonists (PPAR), GLP-1 agonists, DPP-4 inhibitors, or SGLT-2 inhibitors, could reduce the rates of NAFLD progression [40,41,42]. Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.